申请人:Takeda Pharmaceutical Company Limited
公开号:US10654874B2
公开(公告)日:2020-05-19
Provided is a compound represented by the formula (I):
wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
本文提供了一种由式 (I) 表示的化合物:
其中各符号如说明书中所定义,或其盐,具有 AMPA(α-氨基-3-羟基-5-甲基-4-异恶唑丙酸)受体增效作用。本发明化合物可用作抑郁症、精神分裂症、阿尔茨海默病或注意力缺陷多动障碍(ADHD)等疾病的预防或治疗药物。